Overall, the renal anemia therapy market will expand over the 2017-2027 study period, fueled by the increasing prevalence of this complication of chronic kidney disease and the emergence of a novel drug class that will help fulfill the need for additional therapies. Currently, physicians are limited to iron supplements and erythropoietin-stimulating agents (ESAs), which, although effective, have drawbacks. The hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors are expected to launch during the study period and appear to be able to effectively, safely, and conveniently improve renal anemia. However, to succeed, these novel therapies will have to convince physicians and payers of their safety and efficacy benefits compared with current therapies. In addition, HIF-PH inhibitors will face other major challenges, such as reimbursement hurdles, the availability of biosimilar ESAs, and an increasingly stringent regulatory environment. Despite the promise of the HIF-PH inhibitors, the late-phase renal anemia pipeline is relatively weak; only iron-supplement-based technologies are approaching market entry.

QUESTIONS ANSWERED

  • What opportunities exist for the marketers of the emerging oral HIF-PH inhibitors to promote their noninvasive route of administration, particularly for patients not on dialysis?
  • Will establishing cardiovascular (CV) safety be key for the market uptake of HIF-PH inhibitors given the CV issues associated with current therapies?
  • With the imminent availability of biosimilars in the United States, will emerging therapies offering only incremental improvements over existing therapies struggle?
  • What do key opinion leaders think about iron-based phosphate binders for the treatment of renal anemia?

PRODUCT DESCRIPTION

Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

Table of contents

  • Disease Landscape & Forecast
    • COVID-19
      • COVID-19
    • Key Updates
      • March 2020
      • May 2020
      • November 2018
      • August 2018
      • April 2018
      • October 2017
    • Market Outlook
      • Key Findings
        • Market Overview
      • COVID-19 Areas of Potential Forecast Impact
        • COVID-19: Areas of Potential Forecast Impact
      • Market Drivers and Constraints
        • What Factors Are Driving the Market for Renal Anemia?
        • What Factors Are Constraining the Market for Renal Anemia?
      • Drug-Class-Specific Trends
        • Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors
        • Erythropoietin-Stimulating Agents
        • Iron Supplements
    • Forecast
      • Market Forecast Assumptions - Renal Anemia Nondialysis
      • Market Forecast Assumptions - Renal Anemia Dialysis
      • Market Forecast Dashboard - Renal Anemia Nondialysis
      • Market Forecast Dashboard - Renal Anemia Dialysis
    • Etiology and Pathophysiology
      • Disease Overview
      • Etiology
      • Pathophysiology
      • Disease Progression
      • Key Pathways and Drug Targets
    • Epidemiology
      • Key Findings
      • Epidemiology Populations
        • Total Prevalent Cases of Renal Anemia
        • Total Prevalent Cases of Renal Anemia by Dialysis
        • Diagnosed Prevalent Cases of Renal Anemia
        • Drug-Treated Cases of Renal Anemia
    • Current Treatment
      • Key Findings
      • Treatment Goals
      • Key Current Therapies
        • Overview
        • Short-Acting Erythropoietin-Stimulating Agents
        • Long-Acting Erythropoietin-Stimulating Agents
        • Iron-Based Phosphate Binders
        • Iron Supplementation
      • Medical Practice
        • Overview
        • Treatment Guidelines
        • Region-Specific Treatment Practices
    • Unmet Need Overview
      • Current and Future Attainment of Unmet Needs in Renal Anemia
    • Emerging Therapies
      • Key Findings
      • Key Emerging Therapies
        • Notable Developments Among Key Emerging Therapies for Renal Anemia
        • Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors
      • Early-Phase Pipeline Analysis
        • Notable Developments in the Early-Phase Pipeline for Renal Anemia
    • Access & Reimbursement Overview
      • Region-Specific Reimbursement Practices
        • United States
        • EU5
        • Japan
        • Looking for More?
    • Methodology
      • Bottom-Up Forecasting Overview
        • Patient Populations
        • Drug-Specific Assumptions
      • Bottom-Up Forecast Assumptions
        • General Sources of Data
        • General Statements About Pricing
        • Dosing, Days of Therapy, and Compliance
        • Generic Erosion
        • Biosimilar Erosion
        • Out-Year Forecasting
        • Emerging Therapy Prices
      • Primary Market Research
        • Experts Interviewed
    • Appendix
      • Renal Anemia Bibliography

Author(s): Tim Blackstock, MB, ChB, MPhil; Amy Bradshaw Kaiser, MS; Jihan Khan, PhD

Tim Blackstock, is a Director in Decision Resources Group’s Cardiovascular, Metabolic, Renal and Hematologic Disorders team focusing on dyslipidemia, obesity, and non-alcoholic steatohepatitis (NASH). In this role, he evaluates the latest primary and secondary research, as well as available commercial information, to forecast the potential of developmental drugs and provide insight on the various dynamics affecting relevant markets, as well as overseeing the work of team analysts across various metabolic and renal indications. Tim holds a bachelor degrees in medicine and surgery from the University of Otago, New Zealand, and practiced medicine for five years, rotating through various specialties, including internal medicine, general surgery, and psychiatry. Prior to joining DRG, he was a writer in the medical communications industry, developing content for various media, as well as providing editorial assistance to leading pharmaceutical companies and medical experts across a variety of therapeutic areas.

Amy Kaiser joined Decision Resources Group as an associate epidemiologist in 2017. Her focus is on the epidemiology of infectious diseases and niche and rare diseases. She holds an MS in Epidemiology from the University of Massachusetts, Amherst and a BA in International Relations from Mount Holyoke College. Prior to joining Decision Resources Group, she worked as a human health research associate at a environmental consulting firm where her epidemiology research focused on occupational and environmental exposures and associated outcomes.

Jihan Khan, is a director in the oncology team at DRG. Dr. Khan manages a team of analysts who conduct extensive primary and secondary market research on several oncology indications across the major pharmaceutical markets. She also provides sales and client support across DRG oncology products.   Previously, Dr. Khan was a principal analyst on the cardiometabolic team at DRG. Her specialties were the type 2 diabetes and renal disorders markets. Dr. Khan provided forecasts of these pharmaceutical markets by evaluating the agents in development and the changing clinical behaviors and conducting primary research with payers and physicians. Prior to joining DRG, she worked as a knowledge specialist in a company where she conducted in-depth research on products and processes for commercialization. She obtained her in organic chemistry from Brandeis University and was a postdoctoral fellow at Brigham and Women’s Hospital and Harvard Medical School.


Related Reports

Renal Anemia | Unmet Need | Detailed, Expanded Analysis (US & EU)

September 2019 Physicians treating renal anemia are limited to iron supplements and erythropoiesis-stimulating agents (ESA...

View Details